Progress in the development of a cervical cancer vaccine

Therapeutics and Clinical Risk Management

Volumn 2, Issue 3, 2006, Pages 259-269

  Winters, Ursula ^a   Roden, Richard ^b   Kitchener, Henry ^c   Stern, Peter ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cervical cancer; HPV; Vaccine

Indexed keywords

DENDRITIC CELL VACCINE; DNA VACCINE; HEPATITIS A VACCINE; PLACEBO; SGN 00101; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS PROTEIN; VIRUS VACCINE; VIRUS VECTOR; WART VIRUS VACCINE;

ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DISEASE COURSE; DRUG INDICATION; GENOTYPE; HLA MATCHING; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNITY; LASER SURGERY; NONHUMAN; PREVALENCE; REVIEW; SCREENING TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VACCINE PRODUCTION; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CARCINOGENESIS; VIRUS DETECTION; VIRUS GENOME; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS TRANSMISSION; VIRUS TYPING; VIRUS VIRULENCE; WART VIRUS;

EID: 33748456413     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2006.2.3.259     Document Type: Review

References (63)

1. Bosch FX, Manos MM, Munoz N, et al. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst, 87:796-802.
2. Breitburd F, Kirnbauer R, Hubbert NL, et al. 1995. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol, 69:3959-63.
3. Chandrachud LM, Grindlay GJ, McGarvie GM, et al. 1995. Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4, Virology, 211:204-8.
4. Corona Gutierrez CM, Tinoco A, Navarro T, et al. 2004. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther, 15:421-31.
5. Cuzick J, Szarewski A, Cubie H, et al. 2003. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet, 362:1871-6.
6. Davidson EJ, Boswell CM, Sehr P, et al. 2003. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res, 63:6032-41.
7. Davidson EJ, Faulkner RL, Sehr P, et al. 2004. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia. patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine, 22:2722-9.
8. de Jong A, O'Neill T, Khan AY, et al. 2002. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine, 20:3456-64.
9. [DOH] Department of Health. 2005. Joint committee on vaccination and immunisation [online]. Accessed 3 December 2005. URL: http://www.advisorybodies.doh.gov.uk/JCVI/index.htm.
10. Doorbar J. 2005. The papillomavirus life cycle. J Clin Vrol, 32(Suppl 1):S7-15.
11. Dubin G, Colau B, Zahaf T, et al. 2005. Cross-protection against persistent HPV infection, abnormal cytology and CIN associated with HPV-16 and 18 related HPV types by a HPV 16/18 L1 virus-like particle vaccine. 22nd International Papillomavirus Conference, April 30 - May 6, Vancouver, Canada. p 32.
12. Einstein MH, Kadish AS, Burk RD, et al. 2005. Heat shock protein (HSP)-based immunotherapy (HSPE7) for treatment of CINIII (NCI 5850, NYGOG). Gynecol Oncol, 96:912-13.
13. Embers ME, Budgeon LR, Pickel M, et al. 2002. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol, 76:9798-805.
14. Ferlay J, Bray F, Pisani P, et al. 2001. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, Version 1.0. (IARC Cancer Base No. 5) Lyon, France: IARC Pr.
15. Ferrara A, Nonn M, Sehr P, et al. 2003. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol, 129:521-30.
16. Frazer IH. 2004. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol, 4:46-54.
17. Frazer IH, Quinn M, Nicklin JL, et al. 2004. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine, 23:172-81.
18. Gambhira R, Bossis I, Viscidi R, et al. 2005. Cross-neutralising antibody response of healthy volunteers vaccinated with human papillomavirus (HPV) 16 minor capsid protein L2. 22nd International Papillomavirus Conference, April 30 - May 6, Vancouver, Canada. p 227.
19. Garcia F, Petry KU, Muderspach L, et al. 2004. ZYC101 a for treatment of high grade intraepithelial neoplasia. A randomised controlled trial. Obstet Gynecol, 103:317-26.
20. Garrido F, Ruiz-Cabello F, Cabrera T, et al. 1997. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today, 18:89-95.
21. Ghim SJ, Jenson AB, Schlegel R. 1992. HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology, 190:548-52.
22. Goldie SJ, Kohli M, Grima D, et al. 2004. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst, 96:604-15.
23. Hallez S, Simon P, Maudoux F, et al. 2004. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother, 53:642-50.
24. Harper DM, Franco EL, Wheeler C, et al. 2004 Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, 364:1757-65.
25. [IARC] International Agency for Research on Cancer. 2005. Cervix cancer screening. Lyon, France: IARC Pr.
26. Kadish AS, Einstein MH. 2005. Vaccine strategies for human papillomavirus-associatcd cancers. Curr Opin Oncol, 17:456-61.
27. Kaufmann AM, Stern PL, Rankin EM, et al. 2002. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res, 8:3676-85.
28. Kirnbauer R, Booy F, Cheng N, et al. 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A, 89:12180-4.
29. Kirnbauer R, Chandrachud LM, O'Neil BW, et al. 1996. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology, 219:37-44.
30. Kitchener H, Almonte M, Wheeler P, et al. 2005. The ARTISTIC trial of HPV testing in primary cervical screening: methods and baseline data. 22nd International Papillomavirus Conference, April 30 - May 6, Vancouver, Canada. p 22.
31. Koutsky LA, Ault KA, Wheeler CM, et al. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med, 347:1645-51.
32. Mahdavi A, Monk BJ. 2005. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist, 10: 528-38.
33. Mao C, Koutsky L, Ault KA, et al. 2006. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. Obstet Gynecol, 107:18-27.
34. Markowitz L, Dunne E, Gilsdorf J. 2005. Development of recommendations for HPV vaccine use in the United States. 22nd International Papillomavirus Conference, April 30 - May 6, Vancouver, Canada. p 35.
35. Martin-Hirsch PL, Paraskevaidis E, Kitchener H. 1999. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev, Issue 3.
36. Muderspach L, Wilczynski S, Roman L, et al. 2000. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res, 6:3406-16.
37. Munoz N, Bosch FX, Castellsague X, et al. 2004. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer, 111:278-85.
38. [NCI] National Cancer Institute. 2005. Clinical trials [online]. Accessed 22 November 2005. URL: http://www.cancer.gov/clinicaltrials.
39. [NHSCSP] NHS Cervical Screening Programme. 2004. Colposcopy and programme management: guidelines for the NHS Cervical Screening Programme. Sheffield, UK: NHSCSP Publication No. 20.
40. [ONS] Office for National Statistics. 2005a. Cancer registrations in England 2003. National Statistics [online]. Accessed 3 December 2005. URL: http://www.statistics.gov.uk/statbase/Expodata/Spreadsheets/ D9096.xls.
41. [ONS] Office for National Statistics. 2005b. Update to cancer trends in England and Wales 1950-1999. National statistics [online]. Accessed 3 December 2005. URL: http://www.statistics.gov.uk/downloads/theme_health/ CancerTrendsUpdates.pdf.
42. Parkin DM. 2005. World burden of infection-associated cancers. 22nd International Papillomavirus Conference, April 30 - May 6, Vancouver, Canada. p 10.
43. Parkin DM, Bray F, Ferlay J, et al. 2005. Global cancer statistics, 2002. CA Cancer J Clin, 55:74-108.
44. Pastrana DV, Gambhira R, Buck CB, et al. 2005. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology, 337:365-72.
45. Peto J, Gilham C, Fletcher O, et al. 2004. The cervical cancer epidemic that screening has prevented in the UK. Lancet, 364:249-56.
46. Prendiville W, Cullimore J, Norman S. 1989. Large loop excision of the transformation zone (LLETZ). A new method of management for women with cervical intraepithelial neoplasia. Br J Obstet Gynaecol, 96:1054-60.
47. Ressing ME, van Driel WJ, Brandt RM, et al. 2000. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother, 23:255-66.
48. Roden RB, Greenstone HL, Kimbauer R, et al. 1996. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol, 70:5875-83.
49. Rose RC, Reichman RC, Bonnez W. 1994. Human papillomavirus (HPV) type II recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol, 75(Pt 8):2075-9.
50. Skjeldestad FE. 2005 Prophylactic quadrivalent human papillomavirus (HPV) (Types 6,11,16,18) L1 virus-like particle (VLP) vaccine (Gardasil™) reduces cervical intraepithelial neoplasia (CIN 2/3 risk. 43rd Annual Meeting of IDSA, October 6-9, San Francisco, USA. p 53.
51. Smith KL, Tristram A, Gallagher KM, et al. 2005. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV 18. Int Immunol, 17:167-76.
52. Smyth LJ, Van Poelgeest MI, Davidson EJ, et al. 2004. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res, 10:2954-61.
53. Stern PL, Faulkner R, Veranes E, et al. 2001. The role of human papillomavirus vaccines in cervical neoplasia. In: Kitchener HC (ed). Human papillomavirus: best practice in clinical obstetrics and gynaecology. London: Balliere Tindall. p 783-99.
54. Stern PL. 2005. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol, 32(Suppl 1):S72-S81.
55. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. 1995. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A, 92:11553-7.
56. Vambutas A, DeVoti J, Nouri M, et al. 2005. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine, 23:5271-80.
57. Villa LL, Costa RL, Petta CA, et al. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 6:271-8.
58. Walboomers JM, Jacobs MV, Manos MM, et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189:12-19.
59. Waller J, McCaffery K, Forrest S, et al. 2003. Awareness of human papillomavirus among women attending a well woman clinic. Sex Transm Infect, 79:320-2.
60. Wood JM, Levandowski RA. 2003. The influenza vaccine licensing process. Vaccine, 21:1786-8.
61. Zhou J, Sun XY, Stenzel DJ, et al. 1991. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology, 185:251-7.
62. zur Hausen H, de Villiers EM, Gissmann L. 1981. Papillomavirus infections and human genital cancer. Gynecol Oncol, 12:S124-8.
63. Zwaveling S, Ferreira Mota SC, Nouta J, et al. 2002. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol, 169:350-8.